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EXECUTIVE SUMMARY 
Prisoners experience very high rates of drug dependence, health problems and premature 
mortality. Without intervention they are highly likely to come into further contact with the 
criminal justice system, creating further health risk. Opioid dependence is a common problem 
among prisoners, and opioid substitution therapy (with methadone and buprenorphine) for 
opioid dependence may be an effective intervention in preventing morbidity, mortality and 
offending. Using retrospective data linkage, this study evaluated engagement with treatment, 
patterns of offending, incarceration and mortality among opioid-dependent people who received 
OST in New South Wales, Australia, at some time between 1985-2010. We linked all OST 
records with data on all court appearances 1993-2011, custody episodes 2000-2012, and mortality 
1985-2012. 
A total of 638,545 charges were laid against cohort members between 1993-2011. Eight in ten 
males (79.7%) and 67.9 percent of females had at least one charge; rates were 94.15 per 100 PY 
(95% CI 93.89-94.41) among males, and 53.19 per 100 PY (95% CI 52.91-53.46) among females, 
and highest at 15-19 years (175.74 per 100 PY males (95% CI 174.45-177.03), 75.60 per 100 PY 
females (95% CI 74.46-76.76)) and 20-24 years (144.61 per 100 PY males (95% CI 143.70-
145.53), 84.50 per 100 PY females (95% CI 83.53-85.48)). The most frequent charges were theft 
(24.5% of all charges), traffic/vehicle offences (16.3%), offences against justice procedures 
(10.5%), illicit drug offences (10.0%), intentional injury offences (9.9%) and public order 
offences (8.9%).  
Almost four in ten of the cohort (37%; 43% of men and 24% of women) had at least one 
episode of incarceration between 2000-2012. Men had a median of 3 (ranging between 1-47) 
incarcerations, and women, 2 (ranging between 1-35). Costs of incarceration of this cohort 
between 2000 and 2012 totalled nearly AUD$3 billion. Our findings suggest that a substantial 
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minority of opioid dependent people experience incarceration, usually on multiple occasions and 
at significant cost.  
Of the 34,962 people in the cohort, 6,830 were Indigenous and 28,132 were non-Indigenous. 
Among the 6,830 Indigenous people, 4,615 (67.6%) were male and 2,215 (32.4%) female. The 
median number of charges against Indigenous people (25, IQR 31) was significantly greater than 
non-Indigenous people (9, IQR 16) (p<0.001). The median proportion of follow-up time that 
Indigenous males and females spent in custody was twice that of non-Indigenous males (21.6% 
vs. 10.1%, p<0.001) and females (6.1% vs. 2.9%, p<0.001). The proportion of Indigenous 
people who first commenced OST in prison (30.2%) was three times that of non-Indigenous 
people (11.2%) (p<0.001).  
Following on from our study of patterns of offending among opioid-dependent people, we also 
examined the effect of OST treatment and retention on crime rates among 10,744 opioid-
dependent people who first entered OST on or after 1 January 2004. This allowed a comparison 
of crime rates in the four years immediately prior to treatment entry (the average time before an 
individual enters treatment after becoming opioid dependent), as well as periods in and out of 
OST after initiating treatment. We adjusted for time spent in custody over this period.  
The crude crime rate (CCR) per 100 person-years for all offences that individuals were charged 
with prior to treatment entry was 130.78 (95% CI 129.65-131.91). A 32% reduction was 
observed while individuals were in OST [CCR per 100PY 88.29, 95% CI 86.96-89.63] and a 20 
percent reduction was observed while individuals were out of OST [CCR per 100PY 101.67, 
95% CI 100.35-102.99]. When comparing the crime rates after treatment entry only, being out of 
treatment was associated with a 15% increase, compared to the ratre during time spent in 
treatment. 
We found that cohort members were in prison for 30,998 person-years (PY), during which time 
there were 51 deaths. The all-cause crude mortality rate (CMR) in prison was 1.6 per 1,000 PY 
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(95% CI: 1.2, 2.2 per 1,000 PY), and the unnatural death CMR was 1.1 per 1,000 PY (95% CI: 
0.8, 1.6 per 1,000 PY). Compared to prison time spent out of OST, the hazard of all-cause death 
was 74 percent lower while in OST in prison (adjusted hazard ratio (AHR): 0.26; 95% CI: 0.13 to 
0.50), and the hazard of unnatural death was 87 percent lower while in OST (AHR: 0.13; 95% 
CI: 0.05 to 0.35). Compared to periods not in OST, the hazard of all-cause death during the first 
four weeks of incarceration was 94% lower while in OST (AHR: 0.06; 95% CI: 0.01 to 0.48).  
There were 100,978 person-years of follow-up post-release, during which time 1,050 deaths 
occurred, for a CMR of 10.4 per 1000 person-years (95% CI: 9.8-11.0). Accidental drug-induced 
deaths were the most common cause of death. OST exposure in the four weeks post-release 
reduced the hazard of death by 75% (adjusted hazard ratio 0.25; 95%CI: 0.15, 0.52); OST receipt 
in prison had a short-term protective effect that decayed quickly across time.  
Through the use of a population-wide linkage we were able to avoid the limitations of small, 
selected and possible unrepresentative samples. Our study provides persuasive evidence that 
OST provision in prison and post-release reduces mortality risk in the immediate post-release 
period. We concluded that OST in prison and post-release reduces mortality risk in the 
immediate post-release period. OST in prison should be scaled up, and post-release OST 
continuation maximised. 
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1. INTRODUCTION 
Prisoners are one of the most vulnerable groups in the community, experiencing extremely high 
rates of mental illness, drug and alcohol dependence, chronic health conditions, exposure to 
violence, stigmatisation, social isolation and mortality (Kariminia et al. 2007a). Parental 
incarceration is also associated with negative health and social outcomes for children and families 
(Quilty et al. 2004). The World Health Organization (WHO) states that “Prisoners are members 
of the general population: they come from and usually return to the community. The relation 
between the health of prisoners, their families and the wider community is thus an acute 
concern. Limiting the spread of communicable diseases in prison benefits both prisoners and the 
wider community. Health promotion in prisons – which contributes to the health of prisoners 
and staff by, for example reducing smoking, improving diet and increasing exercise – reduces the 
burdens on a country's health system as a whole.” (World Health Organization 2010). Crime also 
carries costs to the wider community: impacts upon public amenity, financial loss, personal/ 
property damage, and the public health burden associated with premature morbidity and 
mortality of prisoners.  
Prisoners have extremely elevated rates of heroin dependence relative to the general population 
(Butler et al. 2004). Heroin dependence causes significant impacts upon public health and public 
order (Hall et al. 1999), and is thought to have the greatest impact of all illicit drugs, in Australia 
and globally (Begg et al. 2007; Degenhardt et al. 2013b; Nutt et al. 2007). The post-release period 
has been identified as a high risk period for mortality among prisoners (Coffey et al. 2003; 
Merrall et al. 2010; Seaman et al. 1998; Harding-Pink 1990; Christensen et al. 2006; Bird & 
Hutchinson 2003; Binswanger et al. 2007), most of it directly drug-related, with high rates of 
death from drug overdose in the early weeks post-release noted in a number of studies. For the 
first time our study will allow us to quantify the impact and model the cost effectiveness of 
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opioid substitution therapy (OST) in reducing mortality and recidivism among this extremely 
disadvantaged group. 
 
1.1 The association between opioid dependence and crime 
There is a strong association between heroin dependence and criminal activity. Surveys of 
injecting drug users (IDUs) find that more than 50 percent report imprisonment, predominantly 
for property and drug offences (Black et al. 2008). Early studies of heroin users entering 
treatment services found even higher rates of offending: one early study showed 90 percent had 
one or more convictions, 76 percent for drug offences, and 78 percent for property offences 
(Hall et al. 1993). There is evidence that this high conviction rate is directly related to heroin use. 
Daily heroin users report committing robberies at nearly twice the rate of irregular users (i.e. 
heroin use of less than three times/week) (Stevenson & Forsythe 1998); and among those 
convicted of burglary, those who are heroin dependent report committing burglaries at 50 
percent higher rates than those without such drug problems (Stevenson & Forsythe 1998).  
 
1.2 Opioid substitution therapy (OST) 
The mainstay of treatment for opioid dependence is opioid substitution therapy (OST). Both 
methadone and buprenorphine (the two most commonly used medicines) have been listed on 
the WHO’s List of Essential Medicines as core medicines for the treatment of people who are 
opioid dependent (World Health Organization 2005), given strong evidence of their 
effectiveness. Methadone is an orally administered opioid agonist with a half-life of 24–36 hours, 
dosed daily. Buprenorphine is a sublingually administered partial opioid agonist, with a longer 
period of action, allowing less frequent dosing, publically subsidised as a form of OST in 
Australia since 2001 (Burns et al. 2009).  
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Differences in clinical outcomes exist between these two medicines (Mattick et al. 2014). Our 
previous research has demonstrated that buprenorphine clients in NSW are retained for shorter 
periods in treatment; are more likely to cycle in and out of treatment; and are more likely to make 
repeated switches in medicines (Burns et al. 2009). These findings are consistent with evidence 
from randomised controlled trials (RCTs) (Mattick et al. 2014) .   
 
1.3 The impact of OST upon crime 
There is limited direct evidence of the impact of OST on crime. The Cochrane reviews which we 
have contributed to have concluded that further evidence is needed to understand the nature and 
extent of impacts of OST generally, and buprenorphine specifically; no studies have examined its 
impact upon actual criminal activity (charges or convictions), nor compared it to methadone 
(Mattick et al. 2008). Few, if any, RCTs would have sufficient power or follow-up to examine 
these issues with certainty, and certainly not for subgroups who may be at differing risk for 
recidivism or treatment failure. Given the differences in treatment retention mentioned above, it 
is possible that any potential impacts on incidence and rate of re-offending may be attenuated for 
buprenorphine compared to methadone. The current study will have sufficient power to examine 
links between retention in buprenorphine and methadone specifically, levels of offending, 
imprisonment and reoffending, and examine potential variations in the strength of this link 
across different patient groups. 
 
1.4 Provision of OST in prison 
OST is an effective treatment for opioid-dependent prisoners; post-release it is associated with 
reduced heroin use, reduced injecting and injecting risk and higher treatment engagement 
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compared to controls (Stallwitz & Stover 2007; Kinlock et al. 2009; Jürgens et al. 2009). 
Nonetheless, there remains considerable controversy surrounding the implementation and 
expansion of OST in prisons, with inequities in provision of care for opioid dependent people in 
prisons compared to those in the community. Although international agencies have emphasised 
the effectiveness and importance of OST provision within the prison setting (Jürgens et al. 2009; 
Stallwitz & Stover 2007; Larney 2010), policymakers in many countries are resistant to calls for 
the introduction of OST in prison settings (McKenzie et al. 2009). 
 
Reviews of evidence on OST provision in prison have further highlighted a need for careful 
study of the impact of OST in prison (and transfer post-release) upon mortality and recidivism 
post-release, arguing that evidence has not yet been sufficiently powerful or rigorous to examine 
either outcome (Stallwitz & Stover 2007). Comparisons of buprenorphine and methadone have 
never been undertaken before. The current study will conduct the following: a) examine 
mortality risk of opioid dependent prisoners upon release, comparing those successfully 
transferred to community OST with those who are not and b) analyse outcomes across minority 
subgroups. 
 
1.5 The impact of OST in selected priority subgroups 
Some subgroups of opioid dependent people are at elevated risk, but research to date has been 
limited due to low power. Subgroup analysis is important if there are potentially large differences 
between groups in the risk of a poor outcome (Rothwell 2005), and we believe this may be the 
case with some groups in our research. Subgroup analyses need to be predefined, carefully 
justified and limited to clinically important questions (Rothwell 2005), so are rarely undertaken in 
RCTs. Here, we describe such a rationale for two groups: Indigenous (Aboriginal and/or Torres 
Strait Islander) Australians, and women. 
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Indigenous Australians are highly overrepresented among samples of primary heroin IDUs 
(Phillips & Burns 2009) and are 12 times more likely to be incarcerated than non-Indigenous 
Australians (Snowball & Weatherburn 2006). The overrepresentation is strongly associated with  
drug and alcohol use, even after controlling for other correlates of Indigenous imprisonment 
(Weatherburn 2008). Despite this, no specific analyses of mortality risk among Indigenous opioid 
dependent prisoners have ever been undertaken; an intervention such as OST could serve to 
significantly decrease both mortality and recidivism among this group.  
Health outcomes for drug dependent women are worse than those of men, particularly with 
respect to mental health, exposure to violence, engagement in sex work, and drug-related 
physical problems. Physiological differences mean that women advance more rapidly from drug 
use to dependence than men, developing harms more quickly (Hernandez-Avila et al. 2004). The 
mortality elevation for women compared to their age peers is greater than that for men 
(Degenhardt et al. 2009). Although women are less likely to be incarcerated than males, the 
number being incarcerated in Australia is increasing at a faster rate than for men: a 57 percent 
increase from 1999-2009, compared to a 35 percent increase for males (Australian Bureau of 
Statistics 2009). Drug offences are among the most common offences for which women are 
incarcerated, reflecting a high levels of drug dependence (Butler et al. 2004).  
It is therefore timely that an analysis is undertaken of the impact of OST on in-prison and post-
release mortality and crime among female prisoners. Research in this area is lacking: RCT trials 
of OST are largely based on male samples; if women are included, they are generally minorities 
with gender included (if at all) as a covariate (Kinlock et al. 2009). Our study will provide first 
studies of OST impacts upon mortality post-release among women. 
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1.6 The association between OST and mortality  
Opioid dependent people have significantly elevated mortality compared to the general 
population (Darke et al. 2006). OST reduces this mortality risk (Gibson et al. 2008; Degenhardt 
et al. 2009; Davoli et al. 1994; Brugal et al. 2005; Caplehorn & Drummer 1999). Previously we 
have found that the NSW OST program produced a 29 percent reduction in mortality across the 
entire cohort (Degenhardt et al. 2009). Mortality was particularly elevated in the first weeks upon 
leaving treatment, and during induction onto methadone (but not buprenorphine) treatment 
(Degenhardt et al. 2009). 
Heroin dependent prisoners are at particular mortality risk: the post-release period has been 
identified as a high risk period for mortality; with high rates of death from drug overdose in the 
early weeks post-release noted in a number of studies (Coffey et al. 2003; Seaman et al. 1998; 
Harding-Pink 1990; Christensen et al. 2006; Bird & Hutchinson 2003; Binswanger et al. 2007). 
The extent of this elevated mortality rate has been quantified in the United Kingdom: deaths in 
the first 45 days were four times higher than in the first year post-release (Harding-Pink 1990); 
the relative risk of death in the first two weeks post-release was 4.4 (Christensen et al. 2006) or 
seven times higher than in the following 10 weeks (Seaman et al. 1998). One Australian study 
found increased mortality risk for deaths due to suicide and overdose in the period immediately 
after release from prison (Kariminia et al. 2007b). There is evidence that this heightened risk is 
attributable to low opioid tolerance, residual psychological problems and a lack of social support 
(Harding-Pink 1990). No study has examined the impact of treatment with OST in prison, and 
following release, among opioid dependent prisoners compared to those who do not receive 
such treatment, and those without opioid dependence, during an extended period.  
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1.7 The importance of data linkage  
The benefits of using linked population data are that the entire sample is included (ascertainment 
is unbiased), large sample sizes allow the investigation of rare outcomes, the results are highly 
generalisable and the costs are much lower than gathering the same information in a prospective 
cohort study. Data linkage is increasingly recognised as having unique potential as a means of 
monitoring and evaluating  health care services (Brook et al. 2008), with important public health 
benefits (Hulse et al. 2005).  
We have previously successfully linked the Pharmaceutical Drugs of Addiction System (PHDAS) 
to the Admitted Patients Data Collection to examine neonatal outcomes among drug dependent 
pregnant women in NSW (Burns & Mattick 2007), and examined mortality rates among 
prisoners in NSW (Kariminia et al. 2005) . More recently, we successfully linked the PHDAS 
data with the National Death Index (NDI). We demonstrated that changes have occurred over 
time in mortality rates and causes (Randall et al. 2011; Degenhardt et al. 2014c); that mortality 
differed during treatment versus out of treatment, and that the impact of OST differed across 
patient subgroups (Degenhardt et al. 2009). Because the relevant treatment information is not 
captured within the PHDAS dataset and treatment administration points are not updated in a 
timely way (personal communication, Pia Salmalainen, NSW Health), we were unable to 
determine when those receiving OST in prison were released from prison or which prisoners 
were successfully transferred to community OST. Linkage of the PHDAS dataset with prison 
records is essential if we are to ascertain the incidence of contacts with the criminal justice 
system, the effect of treatment on time spent in prison, the coverage of OST among prisoners 
and effect of treatment on mortality post-release.  This study will allow us to estimate the extent 
of mortality risk among opioid dependent prisoners and the mortality reductions achieved 
through provision of OST.  
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1.8 The contribution of health economic analyses  
It is important to demonstrate the cost effectiveness of interventions and evidence of cost-
effectiveness is critical when dealing with interventions that are unpopular for political or 
bureaucratic reasons. Incarceration is expensive; net recurrent expenditure on corrective services 
was $2.4 billion in 2007-08 (Steering Committee for the Review of Government Service 
Provision 2009). National expenditure per person in the population, based on net recurrent 
expenditure on corrective services including depreciation, increased in real terms over the last 
five years, from $100 in 2003-04 to $115 in 2007-08 (Steering Committee for the Review of 
Government Service Provision 2009). We know that methadone and buprenorphine 
maintenance therapies have been demonstrated to be cost effective in reducing heroin use and 
have been estimated to be a far cheaper intervention to reduce heroin use than is prison alone 
(Moore et al. 2007). However, conducting a cost-effectiveness analysis showing the costs offset 
by treatment can provide important additional evidence that could provide justification for 
widespread provision of this treatment within prison settings, nationally and internationally. This 
is the first study which has estimated the cost effectiveness of OST in reducing mortality after 
release from prison. 
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1.9 Aims 
In this report, we summarise a range of analyses that have been undertaken during the course of 
this study. Many of these have already been published (Degenhardt et al. 2013a; Larney et al. 
2014; Degenhardt et al. 2014b; Gisev et al. 2014; Degenhardt et al. 2014a), or are currently in the 
process of being peer-reviewed or submitted for publication (Burns et al. under review; Gisev et 
al. in preparation; Gisev et al. under review; Kimber et al. in preparation). For that reason, we 
summarise the key findings from each piece of work here and direct interested readers to full 
details in the published works. 
These papers largely each reflected one of the original aims, although we undertook additional 
work compared to the original proposal (see Aims 1, 2, 7), and some of the papers contained 
information that addressed more than one aim (for example, the papers on mortality in prison 
and post release (Aims 7, 8 and 9) also examined potential gender differences in mortality risk, 
and differences in mortality risk for Indigenous Australians). The publications arising from this 
work included examination of: 
1. The natural history of criminal justice system involvement among opioid dependent 
people, 1993-2011; 
2. The extent of imprisonment of opioid dependent people, 2000-2012; 
3. Potential differences in the impacts of buprenorphine and methadone upon treatment 
retention and mortality; 
4. Differences in OST engagement and crime among Aboriginal and Torres Strait Islanders; 
5. Gender differences in OST engagement; 
6. The association between retention in OST and crime among opioid dependent people; 
7. The impact of opioid substitution therapy (OST) provision in prison upon in-prison 
mortality; 
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8. The impact of OST on mortality following release from prison; 
9. The nature of deaths occurring in prison or immediately post-release; 
10. Cost effectiveness of OST in reducing mortality post-release among this group. 
2. METHODS  
2.1 Ethical approval 
Ethical approval was obtained from the NSW Aboriginal Health and Medical Research Council 
(AHMRC), University of New South Wales, NSW Health’s Population & Health Services 
Research Ethics Committee, the Australian Institute of Health and Welfare, the Alfred Hospital 
(Victoria), Corrective Services NSW, Justice Health and Forensic Mental Health Network, and 
the Department of Justice (Victoria).  
 
2.2  Datasets  
This study involved the linkage of four datasets:  
a. Pharmaceutical Drugs of Addiction System (PHDAS) at NSW Department of Health  
b. National Death Index (NDI) at the Australian Institute of Health and Welfare (AIHW) 
c. Offender Integrated Management System (OIMS) at NSW Department of Corrective 
Services 
d. Reoffending Database (ROD) at the Bureau of Crime Statistics and Research (BOCSAR) 
The data linkage was undertaken by two agencies: AIHW (linking PHDAS and NDI) and the 
Bureau of Crime Statistics and Research (linking PHDAS, OIMS and ROD). The data linkage 
process for the study is summarised in Figure 1. 
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Pharmaceutical Drugs of Addiction System (PHDAS) 
The PHDAS is a database containing records of authorisations by the NSW Department of 
Health for medical practitioners to prescribe drugs of addiction. It is a fully identified database of 
all methadone and buprenorphine (i.e. OST) recipients in NSW, as notified to the NSW 
Pharmaceutical Services Branch since 1985. As proof of identity is required to be shown to the 
prescribing doctor, the name variables are of high quality in this dataset. The database also 
records patient admissions and exits from the treatment program, and the type of 
pharmacotherapy treatment (methadone or buprenorphine) and the reason for exiting treatment.  
National Death Index (NDI) 
The NDI is a fully identified database held by the Australian Institute of Health and Welfare 
(AIHW) and contains mortality data collected from each of the State and Territory Births, 
Deaths and Marriage Registers. It collects information including date, state, and causes of death 
(primary causes for all records, secondary causes for deaths occurring 1997 and later). We have 
previously linked the PHDAS data (1985-2006) with the National Death Index (NDI) through 
the Australian Institute of Health and Welfare (AIHW). 
Offender Integrated Management System (OIMS) 
Offender Integrated Management System (OIMS) is a fully identified administrative database of 
the NSW Department of Corrective Services. An extract from this system known as the 
‘Prisoner database’ containing demographic and criminographic information on all adults in full-
time custody in NSW has been successfully used previously (Kariminia et al. 2005) and BOCSAR 
has institutional access to that dataset. We requested a similar extract from OIMS. 
Reoffending Database (ROD) 
ROD was developed by BOCSAR to investigate reoffending. It is an identified, internally linked 
dataset of court records, and contains records of all finalised court appearances in the Local, 
District and Supreme Courts of NSW. The internal matching process of the ROD database has 
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been previously validated and has a specificity of 99.9 percent and a sensitivity of 93.8 percent 
(Hua & Fitzgerald 2006). 
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Figure 1: Flow chart of linkage process 
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3. RESULTS 
3.1 The natural history of criminal justice system involvement 
among opioid dependent people, 1993-2011 
Studies of offending among people who use drugs typically focus upon small and 
potentially unrepresentative samples. We examined NSW opioid dependent clients’ 
contact with the criminal justice system to develop population-wide measures of 
offending among opioid-dependent people. Full details have been published elsewhere 
(Degenhardt et al. 2013a). 
We examined all entrants (n=48,069) to opioid substitution therapy (OST) for opioid 
dependence in New South Wales, Australia, between 1985 and 2010, with data on court 
appearances from 1 December 1993 to 31 March 2011. We calculated person years (PY) 
of observation and charge rates for major crime categories estimated by sex, age, and 
time. 
A total of 638,545 charges were laid against cohort members during the follow-up 
period. Eight in ten males (79.7%) and 67.9% of females had at least one charge; rates 
were 94.15 per 100 PY (95% CI 93.89-94.41) among males, and 53.19 per 100 PY (95% 
CI 52.91-53.46) among females, and highest at 15-19 years (175.74 per 100 PY males 
(95% CI 174.45-177.03), 75.60 per 100 PY females (95% CI 74.46-76.76)) and 20-24 
years (144.61 per 100 PY males (95% CI 143.70-145.53), 84.50 per 100 PY females (95% 
CI 83.53-85.48)).  
The most frequent charges were theft (24.5% of all charges), traffic/vehicle offences 
(16.3%), offences against justice procedures (10.5%), illicit drug offences (10.0%), 
intentional injury offences (9.9%) and public order offences (8.9%).  
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Overall, 20.8 percent of the cohort accounted for 67.4 percent of charges. The top most 
frequently appearing 5.6 percent of the cohort accounted for 24.3 percent of costs 
($75.5M). Among opioid dependent people in Australia, a minority account for the 
majority of the criminal justice contact and levels of offending are not consistent over 
time, sex or age. 
 
3.2 The extent of imprisonment of opioid dependent people, 2000-
2012 
There are few data about the incarceration of opioid dependent people involving large 
representative cohorts. We aimed to determine the prevalence and duration of 
incarceration in a large cohort of opioid dependent people in Australia using data linkage 
methods, and estimate the costs associated with their incarceration. Full details of this 
work have been published elsewhere (Degenhardt et al. 2014a). 
We conducted a retrospective linkage study of all entrants to OST in NSW, 1985-2010, 
with data on incarceration, 2000-2012 (n=47,196). The number and duration of 
incarcerations were calculated. The average daily cost of incarceration was applied to days 
of incarceration in the cohort to examine the costs associated with incarceration of this 
cohort across the observation period.  
Almost four in ten of the cohort (37%; 43% of men and 24% of women) had at least one 
episode of incarceration lasting one or more days. Men had a median of 3 (ranging 
between 1-47) incarcerations, and women, 2 (ranging between 1-35). Indigenous men 
spent 23 percent of their follow-up time incarcerated, compared with 8 percent for non-
Indigenous men. Similarly, Indigenous women spent a substantially greater proportion of 
time incarcerated than non-Indigenous women (8% vs. 2%).  
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Costs of incarceration of this cohort between 2000 and 2012 totalled nearly AUD$3 
billion. Our findings suggest that a substantial minority of opioid dependent people 
experience incarceration, usually on multiple occasions and at significant cost. Treatment 
for opioid dependence, inside and outside prisons, may help reduce incarceration of this 
cohort. 
 
3.3 Potential differences in the impacts of buprenorphine and 
methadone upon treatment retention and mortality 
As noted earlier, research suggests methadone and buprenorphine may be differentially 
suited to particular groups of people and particular settings. The aims of this study were 
to compare the characteristics of first-time methadone and buprenorphine treatment 
entrants; track treatment discontinuation and re-entry with methadone and 
buprenorphine; and examine the factors associated with an individual’s risk of leaving 
their first OST treatment episode.  Full details or this study are presented elsewhere 
(Burns et al. under review). 
We conducted a retrospective data linkage study of OST entrants (N=32,033) in New 
South Wales (NSW) (August 2001-December 2010) to records of custody episodes 
(January 2000- March 2012). Characteristics of methadone and buprenorphine users were 
compared descriptively and time-dependent Cox proportional hazard models were used 
to examine factors associated with an individual’s risk of leaving their first treatment 
episode.   
There were 15,600 first time OST entrants between 2001 and 2010 - 7,183 (46%) 
commenced buprenorphine and 8,417 (54%) methadone.  Fifty-six percent of those who 
commenced buprenorphine spent fewer than 3 months in treatment, compared to 30 
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percent who commenced methadone.  Retention in treatment at 12 months was higher 
among those commencing methadone (44%) compared to buprenorphine (25%). 
However, 12-month buprenorphine retention increased by 10 percent from 2001-2010, 
whereas methadone retention at this point decreased by 3 percent. Receiving 
buprenorphine in the community was associated with the greatest risk of leaving a first 
treatment episode (Adjusted Hazards Ratio 1.68, 95% CI 1.61-1.75), compared to 
receiving methadone, and prison OST receipt. 
We concluded that individuals commencing methadone are retained longer in treatment 
than those commencing on buprenorphine although buprenorphine retention has 
improved over time.  
 
3.4 Differences in engagement with OST and crime among 
Aboriginal and Torres Strait Islanders  
Although Indigenous Australians are over-represented among heroin users, there has 
been no study examining offending, time in custody, and OST treatment utilisation 
among Indigenous opioid-dependent people at the population level, nor comparing these 
to non-Indigenous opioid-dependent people. The aims of this study were to compare the 
nature and types of offences, time in custody and OST treatment utilisation between 
opioid-dependent Indigenous and non-Indigenous Australians in contact with the 
criminal justice system. Full details can be found elsewhere (Gisev et al. under review). 
We used linked records of OST entrants in New South Wales, Australia (1985-2010), 
court appearances (1993-2011) and custody episodes (2000-2012). Rates of criminal 
charges per 100 person-years were compared between Indigenous and non-Indigenous 
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Australians. Comparisons were made between Indigenous and non-Indigenous 
Australians for time spent in custody, as well as characteristics of OST utilisation.  
Of the 34,962 people in the cohort, 6,830 were Indigenous and 28,132 were non-
Indigenous. Among the 6,830 Indigenous people, 4,615 (67.6%) were male and 2,215 
(32.4%) female. The median number of charges against Indigenous people (25, IQR 31) 
was significantly greater than non-Indigenous people (9, IQR 16) (p<0.001). Overall, 
Indigenous people were charged with 33.2 percent of the total number of offences 
against the cohort and 44.0 percent of all violent offences. The median proportion of 
follow-up time that Indigenous males and females spent in custody was twice that of 
non-Indigenous males (21.6% vs. 10.1%, p<0.001) and females (6.1% vs. 2.9%, 
p<0.001). The proportion of Indigenous people who first commenced OST in prison 
(30.2%) was three times that of non-Indigenous people (11.2%) (p<0.001). Indigenous 
males spent less time in OST compared to non-Indigenous males (median proportion of 
follow-up time in treatment: 40.5% vs. 43.1%, p<0.001). 
Indigenous opioid-dependent people in contact with the criminal justice system are 
charged with a greater number of offences, spend longer in custody and commonly 
initiate OST in prison. Criminal justice system contact is an important opportunity to 
engage Indigenous people in OST.  
 
3.5 Gender differences in OST engagement  
Few population-based studies have examined differences in OST treatment utilisation 
between men and women. Using a population of opioid-dependent people in NSW, first-
episode and long-term OST treatment utilisation profiles between men and women were 
compared, differentiating between treatment initiation in the community and in custody.   
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This was a retrospective data linkage study using records of new OST entrants (2001-
2010), and custody episodes (2000-2012). First OST treatment episode and overall 
treatment utilisation characteristics were compared between men and women initiating 
treatment in the community or in custody. Treatment retention was evaluated at three, 
six, nine and 12 months after first commencing OST, and overall, as the median 
proportion of follow-up time spent in treatment.  
There were 15,600 first-time OST entrants in the cohort during the follow-up period. 
This included 10,930 men (70.1%) and 4,670 women (29.9%). A substantial minority 
initiated treatment in custody (n=3,016, 19.3%). More men than women began OST in 
custody (24.0% vs. 8.3%, p<0.001) and only ever received OST in custody (57.5% vs. 
41.8%, p<0.001). Women were retained longer in their first OST treatment episode at 
three, six, nine and 12 months post-entry into treatment. They also spent more of their 
overall follow-up time in treatment. The median proportion of follow-up time spent in 
treatment was higher among women than men initiating treatment in both the 
community (46.6% (IQR 74.9) vs. 39.1% (IQR 72.4)) and custody (41.3% (IQR 61.4) vs. 
30.8% (IQR 55.1)).    
We concluded that there are a number of key differences in OST treatment utilisation 
profiles between men and women. Whereas men commonly initiate, and only receive, 
OST in custody, treatment retention is higher among women, independent of the setting 
in which treatment is initiated.  
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3.6 The association between retention in OST and crime among 
opioid dependent people 
Following on from our study of patterns of offending among opioid-dependent people, 
we also examined the effect of OST treatment and retention on crime rates among 
10,744 opioid-dependent people who started OST for the first time on or after 1 January 
2004. This allowed a comparison of crime rates in the four years immediately prior to 
treatment entry (the average time lag before an individual enters treatment after 
becoming opioid dependent), as well as periods in and out of OST after initial contact 
with treatment services. Follow-up commenced on the date exactly four years prior to 
entering treatment, and ended on 31 December 2011 or the date of death, whichever was 
earlier. We also accounted for the time spent in custody over this period, including only 
the days that individuals were in the community.  
The crude crime rate (CCR) per 100 person-years for the total number of offences that 
individuals were charged for during the four years prior to treatment entry was 130.78 
(95% CI 129.65-131.91). A 32 percent reduction was observed in the CCR while 
individuals were in OST [CCR 88.29, 95% CI 86.96-89.63] and a 20 percent reduction 
was observed while individuals were out of OST [CCR 101.67, 95% CI 100.35-102.99]. 
When comparing the crime rates after treatment entry only, a 15% increase in the CCR 
was observed over the period in which individuals were not receiving OST.  
The effect of retention in treatment for individuals was evaluated for individuals who 
were in treatment for at least three months (n=7,546), six months (n=6,685), nine 
months (n=6,072) and 12 months (n=5,586). There was a clear reduction in the total 
CCR the longer individuals were in treatment: 85.72 (95% CI 84.40-87.05) at three 
months, 82.78 (95% CI 81.48-84.10) at six months, 79.20 (95% CI 77.91-80.50) at nine 
months and 76.50 (95% CI 75.22-77.80) at 12 months.  
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In summary, entry into OST had a positive effect on reducing crime rates among people 
with established opioid dependence. Lower crime rates were observed during periods in 
OST and greatest reductions were observed among people who were retained longer in 
treatment.  
 
3.7 The impact of opioid substitution therapy (OST) provision in 
prison upon in-prison mortality 
Deaths in prison are a significant concern, and correctional authorities have a 
responsibility to ensure that such deaths are kept to a minimum. Opioid dependent 
people commonly experience imprisonment (as we documented earlier in this cohort), 
and may be at particular risk of death in prison. OST reduces mortality among opioid-
dependent people residing in the community, but it is unclear if this is also the case in 
prison. This paper aimed to describe deaths in prison among opioid-dependent people, 
and examine associations between receipt of opioid substitution therapy and risk of death 
in prison. Full details of this work have been published elsewhere (Larney et al. 2014). 
The cohort in this analysis included all opioid dependent people who had been received 
to adult prison at least once (n=16,715) in NSW between 2000 and 2012. We examined 
rates of mortality during different periods in prison, and examined both natural and 
unnatural (suicide, drug-induced, violent and other injury) deaths in prison.  
We found that cohort members were in prison for 30,998 person-years (PY), during 
which time there were 51 deaths. The all-cause crude mortality rate (CMR) in prison was 
1.6 per 1,000 PY (95% CI: 1.2, 2.2 per 1,000 PY), and the unnatural death CMR was 1.1 
per 1,000 PY (95% CI: 0.8, 1.6 per 1,000 PY).  
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Compared to time out of OST, the hazard of all-cause death was 74 percent lower while 
in OST (adjusted hazard ratio (AHR): 0.26; 95% CI: 0.13 to 0.50), and the hazard of 
unnatural death was 87% lower while in OST (AHR: 0.13; 95% CI: 0.05 to 0.35). The all-
cause and unnatural death CMRs during the first four weeks of incarceration were 6.6 per 
1,000 PY (95% CI: 3.8, 10.6 per 1,000 PY) and 5.5 per 1,000 PY (95% CI: 2.9, 9.4 per 
1,000 PY), respectively. Compared to periods not in OST, the hazard of all-cause death 
during the first four weeks of incarceration was 94 percent lower while in OST (AHR: 
0.06; 95% CI: 0.01 to 0.48), and the hazard of unnatural death was 93 percent lower 
while in OST (AHR: 0.07; 95% CI: 0.01 to 0.53). 
Mortality of opioid-dependent prisoners was significantly lower while in receipt of OST. 
In addition to other known benefits of OST in prison (e.g. reduced opioid use and 
injecting drug use), to-scale provision of OST in prisons will dramatically reduce 
unnatural deaths among opioid-dependent prisoners. 
 
3.8 The impact of OST on mortality following release from prison 
Prisoner populations are growing in many countries worldwide and the immediate period 
post-release from prison carries an extremely high risk of mortality for ex-prisoners, 
particularly among those who use (and return to) drugs (Merrall et al. 2010). 
There has been little evaluation of any interventions to reduce this mortality risk. Despite 
community evidence that OST for opioid dependence reduces mortality risk, no study to 
date has reported the impact of OST treatment, provided during and after incarceration, 
upon mortality in the high-risk first month post-release. This study has been published 
and full details can be obtained elsewhere (Degenhardt et al. 2014b). 
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In this study, a cohort was formed of all opioid dependent people who entered OST in 
NSW between 1985-2010, and who following OST entry, were released from prison at 
least once between 2000-2012 (n=16,453 individuals, who were released 60,161 times 
across this period). We linked data on OST history, court and prison records, and deaths. 
Crude mortality rates (CMRs) were calculated according to OST retention; multivariable 
Cox regressions for post-release periods undertaken to examine the association between 
OST exposure (a time dependent variable) and mortality post-release, for which 
covariates were updated per-release.  
There were 100,978 person-years of follow-up post-release during the study period, 
during which time 1,050 deaths occurred, for a crude mortality rate (CMR) of 10.4 per 
1000 person-years (95% CI: 9.8-11.0). Accidental drug-induced deaths were the most 
common cause of death. 
Most individuals had received OST at some point while incarcerated (76.5%) and 
individuals were receiving OST in around half (51%) of prison releases during this 
period. Lowest post-release mortality was among those continuously retained in OST 
post-release (CMR 4-weeks post-release: 6.4 per 1,000PY; 95% CI: 5.2, 7.8) and highest 
among those with no OST (CMR: 36.7 per 1,000PY; 95% CI: 28.8, 45.9). Multivariable 
Cox regression models showed that OST exposure in the four weeks post-release 
reduced the hazard of death by 75 percent (adjusted hazard ratio 0.25; 95%CI: 0.15, 
0.52); OST receipt in prison had a short-term protective effect that decayed quickly 
across time.  
Our study provides persuasive evidence that OST provision in prison and post-release 
reduces mortality risk in the immediate post-release period. We concluded that OST in 
prison and post-release reduces mortality risk in the immediate post-release period. OST 
in prison should be scaled up, and post-release OST continuation maximised. 
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3.9 Cost effectiveness of OST in reducing mortality post-release 
among this group 
This study aimed to undertake a cost-effectiveness analysis of the immediate uptake of 
OST post-release from prison relative to not receiving OST immediately upon release in 
saving lives in the first six months post-release. Full details of this work are presented 
elsewhere (Gisev et al. in preparation). 
A cohort was initially formed of all opioid dependent people who entered OST between 
1985 and 2010, and who, following first OST entry, were released from prison at least 
once between 2000 and 2012 (Degenhardt et al. 2014b). The first recorded OST episode 
was used as a proxy for the onset of opioid dependence. In order to allow for each 
person to have six months of follow-up, the cost-effectiveness analysis focused on those 
16,073 people who were released on or before 30 June 2011.   
Using information from each individual’s first recorded prison release after commencing 
treatment, we identified two groups of people: those who were released onto OST 
(n=7,892) and those who were not released onto OST (n=8,181). Mortality was 
evaluated at six months after the first prison release. Release onto OST was defined as 
anyone who received OST at any point from the day of release to seven days post-release 
(to account for a possible lag in uptake from prison to the community). People not 
released onto OST were those who did not receive OST on the day of release and who 
had no evidence of entering treatment in the first seven days after release. Individuals 
who received OST on the day of release but who did not receive any treatment in the 
seven days post-release were also considered the no treatment group (n=344).   
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Costs and resources included were all OST received by both groups in the six months 
follow-up (as measured in AUD2012), costs to the criminal justice system (proven 
charges processed by the court, police, penalties, prison) as well as the social costs of 
crime from the first day post-release to death, or 180 days post-release (whichever 
occurred first). 
The crude average costs incurred per person across treatment, police, courts, penalties, 
custody and the social costs of crime, for the first six months post release, were estimated 
for each group: those released onto OST and those not released onto OST. These were 
$14,962 per person for those released onto OST and $11,878 for those not released onto 
OST. In total across the six month period, there were 35 fewer deaths observed among 
those released onto OST. This equates to a cost of about $88.14 per death prevented.  
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4. SUMMARY AND DISCUSSION 
This study has served to elucidate the patterns of offending, engagement with treatment 
and incarceration of all opioid dependent people in NSW across more than two decades.  
There have been few population-based linkage studies of all criminal charges for an 
entire population of opioid dependent people. Most cohort members (75.8%) had 
appeared before court for criminal charges, with men more likely to do so, and more 
likely to do so on a larger number of occasions than women.  
We found that during 2000-2012, over one-third of the cohort was incarcerated at least 
once, typically more often, and that the costs associated with this are considerable. In any 
given year, around one in seven was incarcerated, with some variation across calendar 
years in such levels. The cumulative incidence of incarceration in the cohort is lower than 
has previously been reported in studies using smaller or convenience samples of opioid 
users or people who inject drugs (Ross et al. 2005; Phillips & Burns 2012), but sensitivity 
analyses suggested that our results were not biased downwards by the inclusion of older 
opioid users in our analysis. Our findings clearly suggest that care should be taken in 
extrapolating incarceration prevalence from selected samples of opioid users, given the 
lower levels in this cohort compared to convenience samples. 
Through the use of a population-wide linkage we were able to avoid the limitations of 
small, selected and possible unrepresentative samples. Although it is possible that opioid 
dependent people who seek treatment differ from those who do not; we are confident in 
the representativeness of this cohort as studies in NSW consistently find that the 
majority of heroin users have received OST at some point in their lives; indeed, in recent 
NSW studies of people who inject drugs, almost six in ten reported currently being in OST 
(Stafford & Burns 2012; Phillips & Burns 2012) and eight in ten an OST history (Kirby 
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Institute 2012). This large-scale linked data study has demonstrated the high mortality 
risk that opioid-dependent prisoners face after prison release, particularly from accidental 
drug-induced deaths, suicide, accidental injury and violence. This is not unexpected 
considering that, upon release, these people often experience poor social support, 
isolation, medical comorbidities, financial stress, debts, and continued exposure to drugs 
in the communities to which they return (Binswanger et al. 2012).  
This study provides unequivocal evidence of the significant benefit of OST on post-
release mortality of opioid dependent people leaving prison. Post-release OST exposure 
was highly effective in reducing the mortality risk in the first month at liberty. The lowest 
mortality rates were seen in those persons who were continuously retained in OST in the 
post-release period, whereas the highest mortality rates were seen in those opioid 
dependent persons with no OST in the post-release period.  
We have demonstrated that OST provided in prison and post-release independently 
reduce mortality in the immediate post-release period. Prison OST is also effective in 
reducing drug-related HIV risk behaviours (Larney 2010), and significantly increases the 
probability that someone will enter OST in the days after release (Kinlock et al. 2007); 
there are also impacts of prison-based and post-release OST on risk of reincarceration 
(Larney et al. 2012). Despite these benefits, considerable inequities remain in the 
provision of care for opioid dependent people in prisons compared with those in the 
community (Harm Reduction International 2012; Nunn et al. 2009). Although 
international agencies have emphasised its effectiveness (Jürgens et al. 2009; Stallwitz & 
Stover 2007), policymakers in many countries are resistant to calls for OST in prison 
settings (McKenzie et al. 2009). In light of the increasingly robust scientific evidence 
demonstrating the benefits of prison OST, continued resistance to implementing and 
expanding OST in correctional settings seems unwarranted.  
Page 39 of 45 
We have demonstrated a clear benefit of post-release OST in preventing death, but 
ensuring recently released prisoners enter and remain in treatment in the community can 
be complex. People released from prison typically have few social supports, inadequate 
housing and employment, limited financial means and complex health needs (Binswanger 
et al. 2012; Baldry et al. 2006). Daily attendance at a clinic, as is often required in order to 
obtain OST, is therefore just one of many competing priorities for releasees, but may 
provide a structure and opportunity for social interaction for those in treatment. As 
noted above, access to treatment while incarcerated increases the likelihood of post-
release treatment entry (Kinlock et al. 2007), but access to in-prison OST is limited in 
many parts of the world (Harm Reduction International 2012; Nunn et al. 2009). 
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